Nuvalent
Cambridge, US · Founded 2017 · Delaware corporation · 2 known investors
Find your way into Nuvalent
284 people in our graph share verified history with the Nuvalent team — schools, employers, funds. One of them is your warm intro.
Adam Valkinunlockedknows Matthew Shair · together at Harvard University (overlapped)
×8knows the team · via Harvard University
×2knows the team · via Manas AI
knows the team · via Columbia University
Nuvalent is a biopharmaceutical company that uses chemistry and structure-based drug discovery to design small-molecule kinase inhibitors as precisely targeted cancer therapies. Its clinical-stage programs address ROS1-, ALK-, and HER2-altered non-small cell lung cancer and other solid tumors.
Founders & leadership
Nuvalent was founded in 2017 by Matthew Shair and Henry Pelish, PhD.
MS
Matthew ShairinCo-founderMatthew Shair is a professor of chemistry and chemical biology at Harvard University whose research focuses on therapeutics development and disease mechanisms. He founded Nuvalent, a biopharmaceutical company developing small-molecule kinase inhibitors for cancer.
HP
Henry Pelish, PhDChief Scientific Officer
RP
R. Porter JamesinCEO
AB
Alex BalcominChief Financial Officer
JP
James Porter, PhDChief Executive Officer
AB
Alex Balcom, MBA, CPAinChief Financial Officer
CT
Christopher Turner, MDChief Medical Officer
BL
Benjamin Lane, PhDChief Technical Operations Officer
DM
Deb Miller, MMSc, PhD, JDChief Legal Officer
DN
Darlene Noci, ALMChief Development Officer
GP
Georg Pirmin Meyer, MDChief International Officer
Board
AH
Investors · 2
Funding
SEC filings, press & company announcements$135M disclosed across 1 of 2 rounds · 2021
- Undisclosed amountSeries AJan 2021Source ↗
▶$135MraisedMay 2021 · 28 investors · Other Health CareRule 506(b)
▶$135MraisedMay 2021 · 28 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Matthew ShairDirector
- Andrew HackDirector
- Cameron WheelerDirector
- Gary GillilandDirector
- Robert JacksonDirector
- Joseph PearlbergDirector
- R. Porter JamesExecutive Officer, Director
- Alex BalcomExecutive Officer
- Offering amount
- $135M
- Amount sold
- $135M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapNuvectis38 shared keywordsNuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.
Robinhood37 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Nuvalent for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nuvalent do?
- Nuvalent is a biopharmaceutical company that uses chemistry and structure-based drug discovery to design small-molecule kinase inhibitors as precisely targeted cancer therapies. Its clinical-stage programs address ROS1-, ALK-, and HER2-altered non-small cell lung cancer and other solid tumors.
- Who founded Nuvalent?
- Nuvalent was founded by Matthew Shair, Henry Pelish, PhD in 2017.
- Who are Nuvalent's investors?
- Nuvalent's investors include Avoro Capital Advisors, Bain Capital Life Sciences.
- How much funding has Nuvalent raised?
- Nuvalent has disclosed $135M raised across 1 of its 2 known rounds.
- Where is Nuvalent headquartered?
- Nuvalent is headquartered in Cambridge, US.